drugset
drugset / Trial / NCT04652297

Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Administration of HS-10356 in Healthy Volunteers

NCT04652297 ↗

Phase 1 Unknown 76 enrolled Jiangsu Hansoh Pharmaceutical Co., Ltd.
RandomizedSequentialDouble-blindTreatment

Summary

The primary objective of this study is to assess the safety and tolerability of single and multiple oral administration of HS-10356 in healthy volunteers.

Timeline

Start
2020-12
Primary completion
2021-08
Completion
2021-08

Drugs

EvaluationDrugModalityDoseRoute
Subject HS-10356 Unknown 2 mg Oral
Subject HS-10356 Unknown 6 mg Oral
Subject HS-10356 Unknown 15 mg Oral
Subject HS-10356 Unknown 30 mg Oral
Subject HS-10356 Unknown 45 mg Oral

Indications

No indication recorded.